Molecular basis for HLA-DQ associations with IDDM

GT Nepom, WW Kwok - Diabetes, 1998 - Am Diabetes Assoc
GT Nepom, WW Kwok
Diabetes, 1998Am Diabetes Assoc
Autoimmune diabetes is the clinical end point for a sequential cascade of immunologic
events that occur in a genetically susceptible individual. Structural and functional analysis of
the HLA class II susceptibility genes in IDDM suggests likely molecular mechanisms for
several of the key steps in this cascade of autoimmune events. We outline a pathway in
which the HLA-DQ genes associated with IDDM bias the immunologic repertoire toward
autoimmune specificities, creating an autoimmune-prone individual, followed by …
Autoimmune diabetes is the clinical end point for a sequential cascade of immunologic events that occur in a genetically susceptible individual. Structural and functional analysis of the HLA class II susceptibility genes in IDDM suggests likely molecular mechanisms for several of the key steps in this cascade of autoimmune events. We outline a pathway in which the HLA-DQ genes associated with IDDM bias the immunologic repertoire toward autoimmune specificities, creating an autoimmune-prone individual, followed by amplification and triggering events that promote subsequent immune activation. There are several direct links between genetics and autoimmune disease in this pathway: the developmental maturation of T-cells in a genetically susceptible individual occurs through molecular interactions between the T-cell receptor and the HLApeptide complex. Selection of T-cells with receptors likely to contribute to autoreactivity may preferentially occur in the context of specific HLA-DQ alleles that are diabetes prone, because of inefficiencies in the peptide-MHC structural interactions of these molecules. Subsequent activation of these T-cells in the context of recognizing islet-associated antigens can trigger a poorly regulated immune response that results in progressive islet destruction. These subsequent diabetes-specific events are also directed by specific HLA genes, most prominently by the binding of specific antigenic peptides by the disease-associated HLA molecules. In this sequential cascade, opportunities for environmental influences and modulation by non-HLA genes are identified that likely act in concert with the predominant genetic susceptibility contributed by the HLA molecules themselves. Clarification of the steps in this pathway extends our understanding of the prevailing role of HLA genes in IDDM pathogenesis and suggests opportunities to intervene at discrete initiating, disease-promoting, or regulatory steps in IDDM development.
Am Diabetes Assoc